Graham Walmsley
Director/Board Member chez AKERO THERAPEUTICS, INC.
Fortune : 54 764 $ au 31/03/2024
Profil
Graham Gordon Walmsley is the founder of Logos Capital Fund LLP, founded in 2019, where he holds the title of Managing Partner.
He is also the founder of Logos Global Management LP, founded in 2019, where he holds the title of General Partner.
Dr. Walmsley's current job(s) include being an Independent Non-Executive Director at Akero Therapeutics, Inc. since 2018, an Independent Director at Olema Pharmaceuticals, Inc. since 2020, and a Director at ALX Oncology, Inc. since 2020.
Dr. Walmsley's former job(s) include being an Independent Director at Lifesci Acquisition II Corp., an Independent Director at ALX Oncology Holdings, Inc. from 2020 to 2021, a Director at Science 37 Holdings, Inc., a Principal at Versant Venture Management LLC from 2016 to 2019, and the Head of Business Development at Jecure Therapeutics, Inc. from 2017 to 2019.
He also served as the Head of Business Development at Contineum Therapeutics, Inc. in 2018.
Dr. Walmsley's education history includes an undergraduate degree from the University of California, Berkeley in 2009 and a doctorate degree from Stanford University School of Medicine in 2016.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AKERO THERAPEUTICS, INC.
0,00% | 08/12/2023 | 2 168 ( 0,00% ) | 54 764 $ | 31/03/2024 |
| 16/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Graham Walmsley
| Sociétés | Poste | Début |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Director/Board Member | 01/06/2018 |
| OLEMA PHARMACEUTICALS, INC. | Director/Board Member | 01/03/2020 |
Logos Capital Fund LLP
 Logos Capital Fund LLP Investment Trusts/Mutual FundsMiscellaneous Logos Capital Fund LLP functions as pooled investment fund. The company is headquartered in Rehoboth, DE. | Founder | 01/08/2019 |
ALX Oncology, Inc.
 ALX Oncology, Inc. Pharmaceuticals: MajorHealth Technology Part of ALX Oncology Holdings, Inc., ALX Oncology, Inc. operates as a clinical-stage immuno-oncology company which develops therapies for cancers. The private company is based in Burlingame, CA. The CEO of the company is Jaume Pons. | Director/Board Member | 01/02/2020 |
Logos Global Management LP
 Logos Global Management LP Investment ManagersFinance Logos Global Management LP (Logos) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Arsani William and Graham Walmsley in 2019. They are owned and controlled by Logos Global Management GP LLC. Logos provides discretionary investment management services to privately offered pooled investment vehicles. | Founder | 01/03/2019 |
Anciens postes connus de Graham Walmsley
| Sociétés | Poste | Fin |
|---|---|---|
| ALX ONCOLOGY HOLDINGS INC. | Director/Board Member | 01/08/2021 |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Private Equity Investor | 01/08/2019 |
Jecure Therapeutics, Inc.
 Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jecure Therapeutics, Inc. provides therapeutic services for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company was founded by Ariel Feldstein in 2015 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/03/2019 |
| CONTINEUM THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2018 |
| ░░░░░░░ ░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Graham Walmsley
| University of California, Berkeley | Undergraduate Degree |
| Stanford University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| AKERO THERAPEUTICS, INC. | Health Technology |
| OLEMA PHARMACEUTICALS, INC. | Health Technology |
| CONTINEUM THERAPEUTICS, INC. | Health Technology |
| ALX ONCOLOGY HOLDINGS INC. | Health Technology |
| SCIENCE 37 HOLDINGS, INC. | Commercial Services |
| Entreprise privées | 6 |
|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Logos Capital Fund LLP
Logos Capital Fund LLP Investment Trusts/Mutual FundsMiscellaneous Logos Capital Fund LLP functions as pooled investment fund. The company is headquartered in Rehoboth, DE. | Miscellaneous |
Jecure Therapeutics, Inc.
Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jecure Therapeutics, Inc. provides therapeutic services for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company was founded by Ariel Feldstein in 2015 and is headquartered in San Diego, CA. | Commercial Services |
ALX Oncology, Inc.
ALX Oncology, Inc. Pharmaceuticals: MajorHealth Technology Part of ALX Oncology Holdings, Inc., ALX Oncology, Inc. operates as a clinical-stage immuno-oncology company which develops therapies for cancers. The private company is based in Burlingame, CA. The CEO of the company is Jaume Pons. | Health Technology |
Logos Global Management LP
Logos Global Management LP Investment ManagersFinance Logos Global Management LP (Logos) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Arsani William and Graham Walmsley in 2019. They are owned and controlled by Logos Global Management GP LLC. Logos provides discretionary investment management services to privately offered pooled investment vehicles. | Finance |
Lifesci Acquisition II Corp.
 Lifesci Acquisition II Corp. Financial ConglomeratesFinance LifeSci Acquisition II Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses for its initial business. The company was founded on December 18, 2019 and is headquartered in New York, NY. | Finance |
